No Data
No Data
Promising Potential of Bicara Therapeutics' Ficerafusp Alfa Drives Buy Rating Amid Encouraging Clinical Data and Growth Opportunities
Wells Fargo Maintains Bicara Therapeutics(BCAX.US) With Sell Rating, Maintains Target Price $8
Analysts' Top Healthcare Picks: Bicara Therapeutics Inc. (BCAX), AstraZeneca (AZN)
Bicara Therapeutics Says Updated Data From Ongoing Phase 1/1b Clinical Trial Of Ficerafusp Alfa In 1L R/M HNSCC To Be Highlighted In Oral Presentation At 2025 ASCO Annual Meeting
Wells Fargo Initiates Bicara Therapeutics(BCAX.US) With Sell Rating, Announces Target Price $8
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday